Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CytomX Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CTMX
Nasdaq
8731
https://cytomx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CytomX Therapeutics Inc
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript
- May 9th, 2024 8:17 pm
Q1 2024 CytomX Therapeutics Inc Earnings Call
- May 9th, 2024 12:12 pm
CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
- May 9th, 2024 8:01 am
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- May 8th, 2024 8:10 pm
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
- May 8th, 2024 8:10 pm
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
- May 7th, 2024 8:15 pm
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
- May 2nd, 2024 12:08 pm
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
- May 1st, 2024 12:00 pm
Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
- Apr 25th, 2024 2:34 pm
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
- Apr 8th, 2024 12:00 pm
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Apr 3rd, 2024 12:00 pm
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
- Mar 21st, 2024 12:00 pm
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
- Mar 18th, 2024 12:00 pm
CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Mar 13th, 2024 10:28 am
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Earnings Call Transcript
- Mar 12th, 2024 12:30 pm
Q4 2023 CytomX Therapeutics Inc Earnings Call
- Mar 12th, 2024 10:46 am
CytomX Therapeutics Inc (CTMX) Reports 2023 Financial Results and Provides Pipeline Update
- Mar 11th, 2024 9:34 pm
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
- Mar 11th, 2024 9:20 pm
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
- Mar 11th, 2024 8:10 pm
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
- Mar 4th, 2024 1:00 pm
Scroll